Platinum-Based Chemotherapy for the Treatment of High-Grade Gastrointestinal and Unknown Primary Neuroendocrine Neoplasms

#694

Introduction: Poorly differentiated neuroendocrine carcinomas (NEC sec. WHO 2010) are rare and aggressive neoplasms arising from different districts throughout the body. Platinum and etoposide regimen has been the most widely used first line treatment in this setting.

Aim(s): To evaluate the efficacy and safety of platinum and etoposide regimen in the setting of gastrointestinal and unknown primary (CUP) advanced neuroendocrine carcinomas.

Materials and methods: Patients with histological diagnosis of gastrointestinal or CUP NEC treated with cisplatin/carboplatin plus etoposide regimen from 1999 to 2012 were included in the study.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Brandi G

Authors: Paragona M, Campana D, Nobili E, Tomassetti P, Biasco G,

Keywords: neuroendocrine, carcinoma, platinum, etoposide,